NCT02892357

Brief Summary

This is a double-blind,randomised,placebo-controlled clinical trial.We would like to investigate the safety and efficacy of Jianpi Qinghua granule(a Chinese herbal compound) combined with half-dose omeprazole in treatment of non-erosive reflux disease(NERD).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
204

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Jan 2017

Typical duration for phase_1

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 2, 2016

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 8, 2016

Completed
4 months until next milestone

Study Start

First participant enrolled

January 1, 2017

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2019

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
Last Updated

August 26, 2019

Status Verified

February 1, 2019

Enrollment Period

2.7 years

First QC Date

September 2, 2016

Last Update Submit

August 20, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change of GERD Q Scale

    GerdQ was developed through the integration of validated questionnaires reflecting psychological problems and the data of diagnoses of GERD in primary and secondary medical institutions. GerdQ is used for the diagnosis and management of GERD with good authenticity and reliability. GerdQ has six items: heartburn, regurgitation, abdominal pain, nausea, sleep disorders and use of OTC medications. The score is evaluated according to the frequency of every item occurred in recent one week. 0 day, 1 day, 2-3 days, 4-7days respectively assessed to the score of 0, 1, 2 and 3 in the items of heartburn, regurgitation, sleep disorders and use of OTC medications. 0 day, 1 day, 2-3 days, 4-7days respectively assessed to the score of 3, 2, 1 and 0 in the items of abdominal pain and nausea.

    6 weeks

Secondary Outcomes (5)

  • Change of TCM Syndrome Questionnaire

    6 weeks

  • Change of 36-Item Short Form Survey Instrument(SF-36)

    6 weeks

  • Change of Patients Report Clinical Outcomes(PRO)

    6 weeks

  • Change of the Hamilton Depression Scale 17 item (HAMD17)

    6 weeks

  • Safety outcomes

    6 weeks

Study Arms (2)

Treatment group

EXPERIMENTAL

Participants in this group take the herbal compound of Jianpi Qinghua granules and half-dose omeprazole tablet.Jianpi Qinghua granule:one bag after 1 hour of breakfast and supper(twice a day) for 4 weeks.Half-dose omeprazole tablet:1 tablet of real omeprazole (10mg) and 1 tablet of Sham(10mg),once a day before breakfast for 4 weeks.

Drug: Treatment group

Control group

ACTIVE COMPARATOR

Participants in this group take the sham herbal granules twice a day as treatment group and two pieces of real omeprazole tablet(10mg each) once a day before breakfast for 4 weeks.

Drug: Control group

Interventions

Jianpi Qinghua granules:twice a day,1 bag a time;10mg omeprazole and 10mg sham ,once a day,all for 4 weeks.

Also known as: Experimental group
Treatment group

sham Jianpi Qinghua granules:twice a day,1 bag a time; 20mg omeprazole once a day ,all for 4 weeks.

Also known as: Omeprazole group
Control group

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aging between 18 and 75 years, able to read and write Chinese;
  • Meet the criteria of diagnosis of NERD
  • GERD Q score\>=8
  • Meet the TCM diagnosis of syndrome of dampness-heat due to spleen deficiency
  • Receiving no other treatments during the study;
  • Voluntarily agreeing with the study protocol and signing a written informed consent.

You may not qualify if:

  • Gastro-duodenal ulcer
  • Infections, inflammations, or obstruction of the small or large intestine
  • History of gastrointestinal cancer, or prior surgery of the stomach or intestine
  • Females who are pregnant or those lacking adequate contraception
  • Unwilling to sign the informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Dongfang Hospital

Beijing, Beijing Municipality, 100000, China

RECRUITING

Guanganmen Hospital

Beijing, Beijing Municipality, 100000, China

RECRUITING

Related Publications (1)

  • Zhang J, Che H, Zhang B, Zhang C, Zhou B, Ji H, Xie J, Shi X, Li X, Wang F, Tang X. JianpiQinghua granule reduced PPI dosage in patients with nonerosive reflux disease: A multicenter, randomized, double-blind, double-dummy, noninferiority study. Phytomedicine. 2021 Jul 15;88:153584. doi: 10.1016/j.phymed.2021.153584. Epub 2021 May 3.

MeSH Terms

Conditions

Non-Erosive Reflux Disease

Interventions

Control Groups

Condition Hierarchy (Ancestors)

Gastroesophageal RefluxEsophageal Motility DisordersDeglutition DisordersEsophageal DiseasesGastrointestinal DiseasesDigestive System Diseases

Intervention Hierarchy (Ancestors)

Epidemiologic Research DesignEpidemiologic MethodsInvestigative TechniquesResearch DesignMethods

Study Officials

  • fengyun Wang, Ph.D

    xi yuan hospital

    STUDY CHAIR

Central Study Contacts

fengyun Wang, Ph.D

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 2, 2016

First Posted

September 8, 2016

Study Start

January 1, 2017

Primary Completion

September 1, 2019

Study Completion

December 1, 2019

Last Updated

August 26, 2019

Record last verified: 2019-02

Data Sharing

IPD Sharing
Will not share

Locations